BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug co...

January 04, 2023 | News

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 (NCT03758417) conducted in China, which evaluated the efficacy and...

January 03, 2023 | News

The Best of 2022: FDA Approvals and the Breakthroughs That Enabled Them

For a field like cancer research, in which progress can sometimes appear to happen slowly, it is especially important to remind ourselves of the crucial ad...

December 31, 2022 | News | By Calley Jones, PhD

GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development

According to the collaboration agreements, WuXi XDC will actively promote GeneQuantum’s proprietary iLDC (intelligent Ligase-dependent Conjugation) a...

December 28, 2022 | News

Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008

The trial is an open-label, dose-escalation study (No. YH008101) that will evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor a...

December 21, 2022 | News

STADA partners with BIAL to bring Ongentys to Parkinson’s patients in Australia

STADA receives from BIAL exclusive rights to market and distribute Ongentys (opicapone) capsules in Australia STADA Specialty Head Bryan Kim: "Ongentys ...

December 19, 2022 | News

Janssen Submits Biologics License Application to U.S. FDA

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and ...

December 12, 2022 | News

Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient tr...

December 09, 2022 | News

FDA grants ODD for new NK treatment

The US FDA has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye diseas...

December 08, 2022 | News

EMA Validates Application for Arpraziquantel to Treat Schistosomiasis in Preschool-Aged Children

Arpraziquantel is a potential new treatment option for the estimated 50 million preschool-aged children with schistosomiasis, one of the most devast...

December 06, 2022 | News

AcuCort signs its first commercial agreement for the company's drug Zeqmelit™

Kamada Ltd., a leading global biopharmaceutical company, has a well-established infrastructure for marketing, sales, and distribution of commercial pharmac...

November 24, 2022 | News

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation ...

November 22, 2022 | News

GSK opens first-in-Singapore high potency manufacturing and testing facility for next generation cancer treatments

S$44m investment in the new high potency manufacturing facility and laboratory further strengthens Jurong site capabilities to launch new products more q...

November 21, 2022 | News

ACROBiosystems Launches a New Logistics Center in Switzerland to Help Accelerate Drug Development throughout Europe

Located at the crossroad between France, Germany, and Switzerland, Basel is an ideal location for convenient shipping and transpor...

November 21, 2022 | News

Stay Connected